A Phase I Dose-Escalation Study of Intravenous 17-Allylaminogeldanamycin (17-AAG) [NSC 330507, IND 57, 966] and Oral Bay 43-9006 [NSC 724772, IND # 69,896] Administered in Patients With Pretreated Advanced Solid Tumors.

Trial Profile

A Phase I Dose-Escalation Study of Intravenous 17-Allylaminogeldanamycin (17-AAG) [NSC 330507, IND 57, 966] and Oral Bay 43-9006 [NSC 724772, IND # 69,896] Administered in Patients With Pretreated Advanced Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Jan 2013

At a glance

  • Drugs Sorafenib (Primary) ; Tanespimycin (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 13 Mar 2012 Actual patient number is 28 according to ClinicalTrials.gov.
    • 13 Mar 2012 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.
    • 13 Mar 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top